×
QQQ   293.37 (+1.58%)
AAPL   145.41 (+1.74%)
MSFT   267.84 (+0.61%)
META   170.89 (+0.66%)
GOOGL   2,347.76 (+2.46%)
AMZN   115.93 (+1.40%)
TSLA   722.70 (+3.96%)
NVDA   156.92 (+3.71%)
NIO   22.23 (+6.72%)
BABA   122.94 (+3.21%)
AMD   78.67 (+4.41%)
MU   58.24 (+1.52%)
CGC   2.70 (+1.89%)
T   21.14 (+0.24%)
GE   62.28 (+1.15%)
F   11.58 (+4.70%)
DIS   96.88 (+0.83%)
AMC   13.64 (+8.51%)
PFE   52.97 (+0.42%)
PYPL   74.50 (+1.72%)
NFLX   188.64 (+2.49%)
QQQ   293.37 (+1.58%)
AAPL   145.41 (+1.74%)
MSFT   267.84 (+0.61%)
META   170.89 (+0.66%)
GOOGL   2,347.76 (+2.46%)
AMZN   115.93 (+1.40%)
TSLA   722.70 (+3.96%)
NVDA   156.92 (+3.71%)
NIO   22.23 (+6.72%)
BABA   122.94 (+3.21%)
AMD   78.67 (+4.41%)
MU   58.24 (+1.52%)
CGC   2.70 (+1.89%)
T   21.14 (+0.24%)
GE   62.28 (+1.15%)
F   11.58 (+4.70%)
DIS   96.88 (+0.83%)
AMC   13.64 (+8.51%)
PFE   52.97 (+0.42%)
PYPL   74.50 (+1.72%)
NFLX   188.64 (+2.49%)
QQQ   293.37 (+1.58%)
AAPL   145.41 (+1.74%)
MSFT   267.84 (+0.61%)
META   170.89 (+0.66%)
GOOGL   2,347.76 (+2.46%)
AMZN   115.93 (+1.40%)
TSLA   722.70 (+3.96%)
NVDA   156.92 (+3.71%)
NIO   22.23 (+6.72%)
BABA   122.94 (+3.21%)
AMD   78.67 (+4.41%)
MU   58.24 (+1.52%)
CGC   2.70 (+1.89%)
T   21.14 (+0.24%)
GE   62.28 (+1.15%)
F   11.58 (+4.70%)
DIS   96.88 (+0.83%)
AMC   13.64 (+8.51%)
PFE   52.97 (+0.42%)
PYPL   74.50 (+1.72%)
NFLX   188.64 (+2.49%)
QQQ   293.37 (+1.58%)
AAPL   145.41 (+1.74%)
MSFT   267.84 (+0.61%)
META   170.89 (+0.66%)
GOOGL   2,347.76 (+2.46%)
AMZN   115.93 (+1.40%)
TSLA   722.70 (+3.96%)
NVDA   156.92 (+3.71%)
NIO   22.23 (+6.72%)
BABA   122.94 (+3.21%)
AMD   78.67 (+4.41%)
MU   58.24 (+1.52%)
CGC   2.70 (+1.89%)
T   21.14 (+0.24%)
GE   62.28 (+1.15%)
F   11.58 (+4.70%)
DIS   96.88 (+0.83%)
AMC   13.64 (+8.51%)
PFE   52.97 (+0.42%)
PYPL   74.50 (+1.72%)
NFLX   188.64 (+2.49%)
NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$2.26
+0.13 (+6.10%)
(As of 07/7/2022 11:46 AM ET)
Add
Compare
Today's Range
$2.12
$2.29
50-Day Range
$1.73
$2.51
52-Week Range
$1.60
$6.91
Volume
21,320 shs
Average Volume
968,007 shs
Market Capitalization
$123.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Strong Buy
3.50 Rating Score
Upside/​Downside
820.1% Upside
$20.33 Price Target
Short Interest
Healthy
20.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to $0.29 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.56 out of 5 stars

Medical Sector

615th out of 1,433 stocks

Pharmaceutical Preparations Industry

300th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

PRTK Stock News Headlines

Paratek Pharmaceuticals Q1 2022 Earnings Preview
Paratek: Q4 Earnings Snapshot
Paratek Pharmaceuticals's Earnings: A Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
207
Year Founded
1996

Company Calendar

Last Earnings
5/04/2022
Today
7/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$20.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+585.8%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.5
Research Coverage
2 Analysts

Profitability

Net Income
$-59,080,000.00
Pretax Margin
-41.88%

Debt

Sales & Book Value

Annual Sales
$130.16 million
Book Value
($2.62) per share

Miscellaneous

Free Float
50,121,000
Market Cap
$123.12 million
Optionable
Optionable
Beta
1.46

Social Links















Paratek Pharmaceuticals Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view top-rated stocks.

What is Paratek Pharmaceuticals' stock price forecast for 2022?

2 brokerages have issued 12 month price objectives for Paratek Pharmaceuticals' stock. Their PRTK stock forecasts range from $11.00 to $30.00. On average, they predict Paratek Pharmaceuticals' share price to reach $20.33 in the next year. This suggests a possible upside of 799.7% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Paratek Pharmaceuticals' stock performed in 2022?

Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of the year. Since then, PRTK shares have decreased by 49.7% and is now trading at $2.26.
View the best growth stocks for 2022 here
.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Paratek Pharmaceuticals
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The specialty pharmaceutical company had revenue of $24.86 million for the quarter, compared to the consensus estimate of $27.15 million. During the same quarter in the previous year, the company earned ($0.39) earnings per share.
View Paratek Pharmaceuticals' earnings history
.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$170.00 million, compared to the consensus revenue estimate of $166.11 million.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA, Exec. Chairman (Age 64, Pay $934.7k)
  • Dr. Evan Loh FACC, FAHA, M.D., CEO & Director (Age 63, Pay $1.07M)
  • Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 55, Pay $735.48k) (LinkedIn Profile)
  • Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 47)
  • Mr. Jason Burdette, Sr. VP of Technical Operations
  • Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
  • Mr. William M. Haskel, Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 60) (LinkedIn Profile)
  • Ms. Karen McGrath, Sr. VP of HR
  • Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 49) (LinkedIn Profile)

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $2.26.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $123.12 million and generates $130.16 million in revenue each year. The specialty pharmaceutical company earns $-59,080,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 207 workers across the globe.

When was Paratek Pharmaceuticals founded?

Paratek Pharmaceuticals was founded in 1996.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for Paratek Pharmaceuticals is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.